CDEK
← All drugs Report issue

silymarin

Botanicalexperimental

Silibinin (INN), also known as silybin (both from Silybum, the generic name of the plant from which it is extracted), is the major active constituent of silymarin, a standardized extract of the milk thistle, containing a mixture of flavonolignans consisting of silibinin, isosilibinin, silychristin, silidianin, and others. Silibinin itself is a mixture of two diastereomers, silybin A and silybin B, in approximately equimolar ratio. Silibinin is used in pure forms as a medication, and more frequently as an active ingredient in milk thistle–derived herbal supplements. — Wikipedia

Clinical trial activity

54 trials · 71 clinical orgs · 0 marketing orgs

Phase 1
7
Phase 2
17
Phase 3
13
Phase 4
12

Earliest trial started Jul 1, 2000 (NCT00030030)

Timeline

2000s

  1. Jan 1, 2000

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2001

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • Unspecified targetUnclear

    unclear

Chemistry & pharmacology

Loading structure…

SMILES

COc1cc(C2Oc3cc(C4Oc5cc(O)cc(O)c5C(=O)C4O)ccc3OC2CO)ccc1O
Mol. weight
482.44 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • siliphos
  • siliphos
  • silymarin
  • silymarin
  • silymarin
  • silymarin
  • silymarin
  • slimarin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07058090Phase 1Jul 31, 2025Liaquat University of Medical & Health Sciences
NCT06922669N/AJun 24, 2025Government of China, Huazhong University of Science and Technology, People's Liberation Army of China, Shandong University, Tianjin Medical University
NCT07123922N/AJun 20, 2025Bangladesh Medical University
NCT07001150Phase 2May 10, 2025Tanta University
NCT06724952Phase 4Dec 10, 2024Tanta University
NCT07293767N/ANov 16, 2024Ain Shams University
NCT06213857N/AFeb 29, 2024Assiut University, Tanta University
NCT06277635N/AFeb 1, 2024Government of Thailand
NCT06114719Phase 3Jan 1, 2023University of Novi Sad
NCT05666765Phase 4Jan 1, 2023Tanta University
NCT05631041Phase 3Dec 31, 2022Tanta University
NCT05595109Phase 2/Phase 3 (Phase 3)Oct 28, 2022Tanta University
NCT05099601Phase 4May 31, 2022Assiut University
NCT05626881N/AMay 1, 2022Sohag University
NCT06425705Phase 2Feb 25, 2022Post-Graduate Medical Institute, Lahore
NCT05144217Phase 2/Phase 3 (Phase 3)Jun 23, 2021Bionorica, Fraunhofer, J. W. Goethe University
NCT04810572N/AMay 31, 2021University of Sao Paulo
NCT04816682Phase 4Mar 17, 2021F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
NCT04490967Phase 4Sep 30, 2020Assiut University
NCT04394208Phase 3Jun 1, 2020Cairo University
Showing 20 of 54 trials
Page 1 / 3

Organizations

Research & Development (71)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Tanta UniversityAcademic/Hospital7642008
National Center for Complementary and Integrative Health (NCCIH)Government5422000
University of North Carolina at Chapel HillAcademic/Hospital5122003
Isfahan UniversityAcademic/Hospital4332006
Assiut UniversityAcademic/Hospital3222020
Harvard UniversityAcademic/Hospital3022006
Madaus IncFor profit3122008
Thomas Jefferson UniversityAcademic/Hospital3022006
University of PennsylvaniaAcademic/Hospital3022006
Huazhong University of Science and TechnologyAcademic/Hospital2022019
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Government2022006
National Institutes of Health (NIH)Government2112001
SC Fiterman Pharma SRLFor profit2122016
University of MarylandAcademic/Hospital2222003
University of PittsburghAcademic/Hospital2012008
Ain Shams UniversityAcademic/Hospital1112024
Alexandria UniversityAcademic/Hospital1012008
Bangladesh Medical UniversityAcademic/Hospital1112025
Banha Fever HospitalAcademic/Hospital1012008
Belupo d.d., Koprivnica, CroatiaFor profit1012017
71 organizations
Page 1 / 4